Published on 18/12/2025
Mastering PSUR, PBRER, and DSUR: Compliance-Ready Guide for Global Safety Submissions
Introduction to PSUR, PBRER, and DSUR and Their Importance
Periodic safety reporting is a cornerstone of pharmacovigilance, ensuring ongoing monitoring of medicines after clinical development and marketing authorization. Three main report types dominate global regulatory submissions: the Periodic Safety Update Report (PSUR), the Periodic Benefit-Risk Evaluation Report (PBRER), and the Development Safety Update Report (DSUR). These reports provide regulators with cumulative safety data, risk-benefit evaluations, and updated safety signals for both investigational and marketed products.
Agencies such as the EMA, FDA, CDSCO, and PMDA mandate these reports to ensure continued patient safety. By 2025, regulators demand harmonized, digital-first reporting in line with ICH E2C and E2F guidelines. For sponsors, mastering these reports is essential to meet global obligations, minimize compliance risks, and build trust with health authorities.
Key Concepts and Regulatory Definitions
Each report type serves a distinct role in pharmacovigilance:
- PSUR (Periodic Safety Update Report): Traditionally required in the EU, providing a cumulative safety overview for approved products.
- PBRER (Periodic Benefit-Risk Evaluation Report): Updated ICH-compliant format replacing PSUR, focusing on ongoing benefit-risk evaluation.
- DSUR (Development Safety Update Report):
These definitions emphasize the lifecycle approach to safety monitoring, spanning from development (DSUR) to post-marketing (PBRER/PSUR).
Applicable Guidelines and Global Frameworks
Periodic safety reports are regulated by harmonized and regional frameworks:
- ICH E2C (R2): Defines PBRER structure and content requirements.
- ICH E2F: Governs DSUR preparation for investigational products.
- EU Requirements: EMA mandates PBRERs via the EURD list, replacing traditional PSURs.
- FDA Guidance: Requires annual reports for INDs and periodic safety submissions for NDAs/BLAs.
- CDSCO: Mandates PSURs for new drugs during the first four years post-approval and DSURs for clinical trials.
- PMDA: Requires periodic reports aligned with ICH E2C and E2F standards.
These frameworks illustrate how regulators converge on harmonized formats while retaining country-specific nuances.
Processes, Workflow, and Submissions
The workflow for preparing and submitting PSURs, PBRERs, and DSURs includes:
- Data Collection: Aggregate data from safety databases, clinical trials, literature, and real-world evidence.
- Signal Detection: Identify new safety signals and evaluate cumulative risk-benefit profiles.
- Drafting Reports: Use ICH templates to prepare PBRERs or DSURs, integrating clinical, nonclinical, and pharmacovigilance data.
- Cross-Functional Review: Regulatory, safety, and medical teams review for accuracy and compliance.
- Submission: Reports submitted electronically in eCTD format to EMA, FDA, CDSCO, or other agencies.
- Regulatory Review: Authorities assess risk-benefit balance and may request additional studies or labelling changes.
Strict timelines apply—DSURs are annual, while PBRERs follow the EMA EURD list schedule. Timely submissions are critical to avoid compliance gaps or penalties.
Tools, Software, or Templates Used
Effective preparation of periodic reports requires specialized resources:
- Pharmacovigilance Databases: Argus, ARISg for case collection and aggregation.
- Signal Detection Tools: Advanced analytics platforms for safety signal analysis.
- ICH-Compliant Templates: Standard templates for DSURs and PBRERs.
- Document Management Systems: Veeva Vault, MasterControl for drafting, review, and version control.
- eCTD Publishing Tools: Lorenz docuBridge, Extedo eCTDmanager for regulatory submission.
These systems streamline data integration, improve consistency, and ensure regulator-ready submissions.
Common Challenges and Best Practices
Sponsors face multiple challenges in preparing periodic safety reports:
- Data Integration: Difficulty aggregating data across global safety databases.
- Timelines: Meeting strict reporting deadlines across multiple jurisdictions.
- Signal Prioritization: Balancing false positives with genuine safety concerns.
- Resource Burden: Preparing comprehensive reports requires significant time and expertise.
Best practices include maintaining live safety databases, establishing SOPs for report preparation, using standardized templates, and conducting internal quality reviews. Engaging cross-functional teams and outsourcing specialized tasks also improves efficiency.
Latest Updates and Strategic Insights
By 2025, PSUR, PBRER, and DSUR submissions are evolving with regulatory and technological trends:
- Digital Submissions: Increased reliance on structured XML formats for safety reporting.
- Global Harmonization: Widespread adoption of PBRER format to replace traditional PSURs.
- AI Integration: Automated drafting tools assist in data aggregation and narrative writing.
- Risk-Based Oversight: Regulators prioritize review of high-risk product reports.
- Transparency: EMA and other agencies publish safety report summaries to enhance public trust.
Strategically, companies must treat periodic safety reports as more than compliance obligations—they are risk communication tools. By leveraging advanced technologies, aligning with global standards, and investing in robust pharmacovigilance governance, sponsors can ensure regulatory success and safeguard patient safety worldwide.